Current Knowledge and Management of Hypersensitivity Reactions to Monoclonal Antibodies-Reference-Cited by-同舟云学术

Current Knowledge and Management of Hypersensitivity Reactions to Monoclonal Antibodies

Published:2017-05 Issue:3 Volume:5 Page:600-609
ISSN:2213-2198
Container-title:The Journal of Allergy and Clinical Immunology: In Practice
language:en
Short-container-title:The Journal of Allergy and Clinical Immunology: In Practice

Author:

Picard Matthieu^ORCID,Galvão Violeta Régnier

Publisher

Elsevier BV

Subject

Immunology and Allergy

Reference100 articles.

1. Therapeutic outcomes, assessments, risk factors and mitigation efforts of immunogenicity of therapeutic protein products;Yin;Cell Immunol,2015

2. Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels;Jani;Rheumatology (Oxford),2016

3. International Nonproprietary Names (INN) for biological and biotechnological substances. Available from: http://www.who.int/medicines/services/inn/BioRev2011.pdf. Accessed September 6, 2016.

4. International Consensus on drug allergy;Demoly;Allergy,2014

5. The incidence and risk factors of infusion-related reactions to rituximab for treating B cell malignancies in a single tertiary hospital;Jung;Oncology,2014

Cited by 107 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immediate Hypersensitivity Reactions to Biologic Drugs in Children with Inflammatory Bowel Diseases;International Archives of Allergy and Immunology;2024-09-04

2. Basophil Activation Test Predicts Cetuximab Anaphylaxis Severity in Alpha-Gal IgE-Positive Patients;Diagnostics;2024-07-01

3. Implementation of an Accelerated Infusion Protocol (90-Minute Infusion) of Rituximab and Its Safety in Patients With Autoimmune Rheumatic Diseases at a Tertiary Veterans Affairs Center;Cureus;2024-05-18

4. Expert consensus on the management of infusion-related reactions (IRRs) in patients with sickle cell disease (SCD) receiving crizanlizumab: a RAND/UCLA modified Delphi panel;Annals of Hematology;2024-04-20

5. Management of infusion-related reactions in cancer therapy: strategies and challenges;ESMO Open;2024-03